Q3 2025 EPS Estimates for McKesson Co. Increased by Analyst (NYSE:MCK)

McKesson Co. (NYSE:MCK) – Equities research analysts at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for shares of McKesson in a research note issued on Monday, April 22nd. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $8.23 for the quarter, up from their previous estimate of $8.14. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for McKesson’s current full-year earnings is $27.59 per share. Leerink Partnrs also issued estimates for McKesson’s Q4 2025 earnings at $8.69 EPS.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, February 7th. The company reported $7.74 earnings per share for the quarter, beating the consensus estimate of $7.05 by $0.69. The company had revenue of $80.90 billion for the quarter, compared to the consensus estimate of $77.93 billion. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. The company’s revenue was up 14.8% on a year-over-year basis. During the same period last year, the business posted $6.90 EPS.

Several other research firms have also recently commented on MCK. Morgan Stanley raised their price target on McKesson from $522.00 to $548.00 and gave the company an “overweight” rating in a report on Monday, April 15th. Citigroup lifted their price objective on McKesson from $530.00 to $575.00 and gave the stock a “buy” rating in a report on Thursday, February 8th. Barclays began coverage on McKesson in a report on Wednesday, January 3rd. They set an “overweight” rating and a $537.00 price objective for the company. Mizuho lifted their price objective on McKesson from $450.00 to $505.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. Finally, StockNews.com raised McKesson from a “buy” rating to a “strong-buy” rating in a report on Thursday. Two analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, McKesson has an average rating of “Moderate Buy” and a consensus price target of $533.50.

McKesson Price Performance

MCK opened at $539.94 on Wednesday. The business has a 50 day simple moving average of $527.50 and a 200-day simple moving average of $488.84. The stock has a market capitalization of $70.95 billion, a P/E ratio of 24.46, a P/E/G ratio of 1.41 and a beta of 0.45. McKesson has a 12 month low of $352.34 and a 12 month high of $543.00.

McKesson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Shareholders of record on Monday, June 3rd will be given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend is Monday, June 3rd. McKesson’s dividend payout ratio (DPR) is presently 11.24%.

Insider Buying and Selling at McKesson

In other McKesson news, EVP Leann B. Smith sold 186 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total transaction of $92,256.00. Following the transaction, the executive vice president now owns 1,511 shares in the company, valued at $749,456. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Leann B. Smith sold 186 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the transaction, the executive vice president now owns 1,511 shares in the company, valued at $749,456. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Brian S. Tyler sold 3,473 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $524.55, for a total value of $1,821,762.15. Following the completion of the transaction, the chief executive officer now owns 43,445 shares in the company, valued at approximately $22,789,074.75. The disclosure for this sale can be found here. 0.21% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Massachusetts Financial Services Co. MA lifted its stake in shares of McKesson by 16.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 5,148,794 shares of the company’s stock worth $2,238,953,000 after acquiring an additional 708,438 shares in the last quarter. Morgan Stanley raised its stake in McKesson by 14.0% during the third quarter. Morgan Stanley now owns 2,398,380 shares of the company’s stock valued at $1,042,937,000 after buying an additional 294,832 shares in the last quarter. Norges Bank acquired a new stake in McKesson during the fourth quarter valued at approximately $1,024,140,000. Putnam Investments LLC raised its stake in McKesson by 3.2% during the fourth quarter. Putnam Investments LLC now owns 1,997,963 shares of the company’s stock valued at $925,017,000 after buying an additional 62,242 shares in the last quarter. Finally, Northern Trust Corp raised its stake in McKesson by 3.3% during the third quarter. Northern Trust Corp now owns 1,595,162 shares of the company’s stock valued at $693,656,000 after buying an additional 50,265 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.